Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma
Sara Mellid(Spanish National Cancer Research Centre), Alberto Cascón(Spanish National Cancer Research Centre), Javier Lanillos(Spanish National Cancer Research Centre), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Juan María Roldán‐Romero(European Bioinformatics Institute), Bruna Calsina(Spanish National Cancer Research Centre), María Monteagudo(Spanish National Cancer Research Centre), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Xavier Matías‐Guiu(Universitat de Lleida), Javier Pardo de Santayana y Coloma(Spanish National Cancer Research Centre), María Santos(Spanish National Cancer Research Centre), Rosa Ayala(Hospital Universitario 12 De Octubre), Cristina Montero‐Conde(Spanish National Cancer Research Centre), Luis J. Leandro‐García(Spanish National Cancer Research Centre), Ángel M. Martínez‐Montes(Spanish National Cancer Research Centre), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III)
Cited by 16
Related Papers
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
<scp>FIGO</scp> staging of endometrial cancer: 2023
|International Journal of Gynecology & Obstetrics|2023|926
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532